Entera Bio (ENTX) EBITDA (2021 - 2026)

Entera Bio has disclosed EBITDA across 6 years of filings, most recently posting -$3.5 million for Q1 2026.

• Quarterly EBITDA fell 38.08% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.6 million (down 23.85% YoY) and the FY2025 annual result came in at -$11.5 million, down 20.28% from the prior year.
• EBITDA slipped to -$3.5 million in Q1 2026, from -$3.0 million in the prior quarter.
• Over five years, EBITDA peaked at -$2.0 million in Q4 2023 and troughed at -$3.8 million in Q1 2022.
• A 5-year average of -$2.7 million and a median of -$2.7 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 63.96% — and 2023, when it surged 42.32%.
• Tracing ENTX's EBITDA over 5 years: stood at -$3.1 million in 2022, then jumped by 36.02% to -$2.0 million in 2023, then dropped by 21.5% to -$2.4 million in 2024, then fell by 27.0% to -$3.0 million in 2025, then decreased by 16.84% to -$3.5 million in 2026.
• Business Quant data shows ENTX's EBITDA at -$3.5 million in Q1 2026, -$3.0 million in Q4 2025, and -$3.3 million in Q3 2025.